Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis

American Journal of Neuroradiology

Volumn 39, Issue 5, 2014, Pages 831-832

  Simon, J H ^a   Bermel, R A ^a   Rudick, R A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; IMAGE ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRACTICE GUIDELINE; BRAIN; EVIDENCE BASED MEDICINE; HUMAN; OUTCOME ASSESSMENT; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SPINAL CORD; TREATMENT OUTCOME; BRAIN ATROPHY; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DISABILITY; INFLAMMATORY DISEASE; NERVE DEGENERATION; NEUROIMAGING; NEUROLOGIC DISEASE ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RELAPSE; REMYELINIZATION; RIO SCORE; SCORING SYSTEM;

BRAIN; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PATIENT OUTCOME ASSESSMENT; SPINAL CORD; TREATMENT OUTCOME;

BETA1 INTERFERON; GADOLINIUM;

EID: 84901064282     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3937     Document Type: Editorial

References (11)

1. Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 2012;8:13-21
2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
3. Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72:779-87
4. Kantarci OH, Pirko I, Rodriguez M. Novel immunomodulatory approaches for the management of multiple sclerosis. Clin Pharmacol Ther 2014;95:32-44
5. Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013;40:307-23
6. Sormani MP, Rio J, Tintore M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013;19:605-12
7. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013;73:95-103
8. Dobson R, Rudick RA, Turner B, et al. Assessing treatment response to interferon-β: is there a role for MRI? Neurology 2014;21;82:248-54
9. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014;75:43-49
10. Fisher E, Lee, JC, Rudick, R. Temporal patterns of brain atrophy in individual multiple sclerosis patients. The American Academy of Neurology's 65th AAN Annual Meeting in San Diego, CA; March 16-23, 2013
11. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers Consensus Guidelines. AJNR Am J Neuroradiol 2006;27:455-61 (Pubitemid 44897861)